Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

D. Boral Capital reissued their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX – Free Report) in a report issued on Wednesday,Benzinga reports. D. Boral Capital currently has a $12.00 price ...

SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...

Quince Therapeutics (QNCX) “announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application ...

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) have received an average recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat reports ...

Kumaraguru Raja, an analyst from Brookline Capital Markets, has initiated a new Buy rating on Quince Therapeutics (QNCX). Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the ...

Allowance to extend into 2036 patent claims related to method of treating patients with A-T using the company’s proprietary EryDex process Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage ...

company reiterates expectation of enrollment completion in second quarter of 2025 and topline results in fourth quarter of 2025 Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the ...